Moreover, FASN inhibitors like TVB-2640 [62], IPI-9119 [63], GSK2194069 [64] or Orlistat [65] are in early research for treating obesity, cancer and other conditions, but their effects on hypothalamic pathways controlling metabolism remain unclear. Here, FASN is linked to cancer.